Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- UBX
- Price
- 0.81
- Stock movement down
- -0.04 (-20.04%)
- Company name
- Unity Biotechnology Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 2.75M
- Ent value
- 26.84M
- Price/Sales
- 1.45
- Price/Book
- 0.19
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -36.92%
- 1 year return
- -87.79%
- 3 year return
- -70.54%
- 5 year return
- -71.40%
- 10 year return
- -
Last updated: 2025-09-15
DIVIDENDS
UBX does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 1.45 |
| Price to Book | 0.19 |
| EV to Sales | 14.11 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 17.21M |
| EPS (TTM) | -1.13 |
| FCF per share (TTM) | -1.48 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 1.90M |
| Gross profit (TTM) | -664.00K |
| Operating income (TTM) | -32.00M |
| Net income (TTM) | -19.05M |
| EPS (TTM) | -1.13 |
| EPS (1y forward) | -0.82 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -34.91% |
| Operating margin (TTM) | -1682.33% |
| Profit margin (TTM) | -1001.47% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 8.90M |
| Net receivables | 0.00 |
| Total current assets | 30.26M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 15.77M |
| Total assets | 47.13M |
| Accounts payable | 1.80M |
| Short/Current long term debt | 20.70M |
| Total current liabilities | 8.78M |
| Total liabilities | 32.99M |
| Shareholder's equity | 14.14M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -22.54M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -24.93M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -134.67% |
| Return on Assets | -40.41% |
| Return on Invested Capital | -106.75% |
| Cash Return on Invested Capital | -139.69% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.15 |
| Daily high | 0.19 |
| Daily low | 0.10 |
| Daily Volume | 1.42M |
| All-time high | 229.70 |
| 1y analyst estimate | 3.25 |
| Beta | 1.06 |
| EPS (TTM) | -1.13 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| UBX | S&P500 | |
| Current price drop from All-time high | -99.93% | -0.20% |
| Highest price drop | -99.93% | -56.47% |
| Date of highest drop | 9 Jul 2025 | 9 Mar 2009 |
| Avg drop from high | -80.59% | -10.99% |
| Avg time to new high | 201 days | 12 days |
| Max time to new high | 1711 days | 1805 days |
COMPANY DETAILS
Marketcap
2.75M
Marketcap category
Small-cap
Description
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. Its lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. The company also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, an a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
Employees
16
Investor relations
-
SEC filings
CEO
Anirvan Ghosh
Country
USA
City
Brisbane
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner